Summary
Background The open-source release of DeepSeek-R1, a high-performing large language model (LLM), enables local deployment in Chinese hospitals. However, empirical data on deployment scale, hospital characteristics, and functional applications are lacking.
Methods We conducted a nationwide cross-sectional survey of 261 hospitals in mainland China that reported local deployment of DeepSeek-R1 between Jan 1 and Mar 8, 2025. Data were collected via web-scraping from verified hospital sources and structured using a hybrid LLM-extraction pipeline. Deployment characteristics, hospital levels, regions, and model parameter distributions were analyzed using descriptive and stratified statistics.
Findings DeepSeek-R1 was locally deployed in hospitals across 93·5% of Chinese provinces, with tertiary hospitals accounting for 84% of deployments. Geographical disparities were evident, with Central South, East, and North China showing higher adoption. Functional applications spanned clinical diagnosis, patient services, hospital management, and traditional Chinese medicine integration. Among hospitals disclosing model parameters, the 671B version was most prevalent (45·2%), particularly in Guangdong. Smaller models (32B, 70B) were applied in diagnosis support and intelligent Q&A, while the 671B supported more complex scenarios like strategic decision-making and quantum security. The overall deployment rate remains low nationwide (0·7%).
Interpretation Local deployment of DeepSeek-R1 in China has expanded rapidly, led by high-level hospitals in economically developed regions. Model selection reflects functional demand and infrastructure capacity. DeepSeek’s broad applicability and open-source nature position it as a scalable solution for advancing AI-driven hospital transformation. However, uneven regional adoption and limited deployment in primary care suggest policy and infrastructural gaps requiring further attention.
Funding This study was supported by the National Social Science Fund of China (23BGL249).
Competing Interest Statement
Mian-mian Yao is the employee of Tigermed Co., Ltd (a clinical research organization). The other authors declare no competing interests.
Funding Statement
The study was supported by the National Social Science Fund of China (23BGL249).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
